Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News XORTX Therapeutics Inc XRTX


Primary Symbol: V.XRTX

Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more

Recent & Breaking News (TSXV:XRTX)

XORTX to Present and Participate in the Sachs 14th Annual European Life Sciences CEO Forum 2021

GlobeNewswire March 9, 2021

XORTX (CSE:XRX) files provisional patent to treat severe viral infection

John Ballem  March 8, 2021

XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

GlobeNewswire March 8, 2021

XORTX Confirms $1 Million in Warrant Exercise Proceeds

GlobeNewswire March 2, 2021

XORTX Participating in WuXI Healthcare Forum

GlobeNewswire March 1, 2021

Bio-Pharma Co. Announces Granting of European Patent for Treating Kidney Disease

Dave Jackson February 22, 2021

XORTX to Present at BIO CEO and Investor Conference

GlobeNewswire February 17, 2021

XORTX Closes Over Subscribed Private Placement

GlobeNewswire February 10, 2021

XORTX Announces Over Subscribed Private Placement

GlobeNewswire February 8, 2021

XORTX Announces Increase to Private Placement

GlobeNewswire January 28, 2021

XORTX Provides Corporate Update; Synopsis of 2020 Achievements and Key Activities for 2021

Accesswire January 19, 2021

XORTX Provides Corporate Update

GlobeNewswire January 19, 2021

XORTX Grants Options

GlobeNewswire January 12, 2021

XORTX Announces Private Placement

GlobeNewswire January 7, 2021

XORTX Announces Grant of European Patent

GlobeNewswire December 29, 2020

IIROC Trade Resumption - XRX

Canada NewsWire November 16, 2020

XORTX Announces Topline Results from Mount Sinai's COVID-19 Clinical Study

GlobeNewswire November 16, 2020

IIROC Trading Halt - XRX

Canada NewsWire November 16, 2020

XORTX Participation in Virtual Conferences

GlobeNewswire October 28, 2020

XORTX Reports Annual & Special Meeting Results

GlobeNewswire October 23, 2020